Replies to post #190313 on Biotech Values

[DewDiligence]

…ENTA gets a higher share from…ex-US sales.

Only for GT4 patients, where Exviera (ABT-333) is not part of the 2-DAA regimen. (This will also be true in the US once the 2-DAA regimen is approved for GT4.)